Half-year report · HY
8086.TEDINET S100X3LO
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥317.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥644.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥312.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥15.3bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥13.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥8.2bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥10.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥12.4bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.1bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥129m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥6.6bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥813m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.15T | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.17T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.17T | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥855.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥858.9bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥297.7bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥311.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥298.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥110.0bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥106.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥104.9bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥101.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥85.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥96.6bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥16.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥68.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥13.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥71.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥54.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥23.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥36.21 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.36 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥0.79 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥32.08 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥0.7 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 20.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥499m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥431m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥40.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥40.3bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥13.1bn |
| Medical Treatment Relatedreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥256.3bn |
| Medical Treatment Relatedreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥252.6bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3.8bn |
| Medical Treatment Relatedreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥23.9bn |
| Medicine Relatedreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥66.7bn |
| Medicine Relatedreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥37.1bn |
| Medicine Relatedreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥29.6bn |
| Medicine Relatedreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.9bn |
| Pharma Packagingreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥31.2bn |
| Pharma Packagingreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥27.2bn |
| Pharma Packagingreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| Pharma Packagingreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥861m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥354.2bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥316.9bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥37.3bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥28.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥357.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥317.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥40.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥28.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥383m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥272m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥39.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥39.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥14.9bn |
| Medical Treatment Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥245.6bn |
| Medical Treatment Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥242.1bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| Medical Treatment Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥24.5bn |
| Medicine Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥68.4bn |
| Medicine Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥38.0bn |
| Medicine Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥30.4bn |
| Medicine Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| Pharma Packagingreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥34.9bn |
| Pharma Packagingreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥31.6bn |
| Pharma Packagingreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.3bn |
| Pharma Packagingreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥931m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥348.9bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥311.6bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥37.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥28.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥351.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥312.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥39.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥28.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 645
| Item | Context | Value | Unit |
|---|---|---|---|
| Dividends income noi | InterimDuration | 207000000 | JPY |
| Other noi | Prior1InterimDuration | 1192000000 | JPY |
| Other noi | InterimDuration | 1274000000 | JPY |
| Non operating income | Prior1InterimDuration | 2607000000 | JPY |
| Non operating income | InterimDuration | 2519000000 | JPY |
| Interest expenses noe | Prior1InterimDuration | 3717000000 | JPY |
| Interest expenses noe | InterimDuration | 4473000000 | JPY |
| Foreign exchange losses noe | Prior1InterimDuration | 4700000000 | JPY |
| Foreign exchange losses noe | InterimDuration | 1308000000 | JPY |
| Equity in losses of affiliates noe | Prior1InterimDuration | 1461000000 | JPY |
| Equity in losses of affiliates noe | InterimDuration | 1922000000 | JPY |
| Other noe | Prior1InterimDuration | 1695000000 | JPY |
| Other noe | InterimDuration | 1917000000 | JPY |
| Non operating expenses | Prior1InterimDuration | 11574000000 | JPY |
| Non operating expenses | InterimDuration | 9622000000 | JPY |
| Ordinary income | Prior1InterimDuration | 4492000000 | JPY |
| Ordinary income | InterimDuration | 8234000000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1InterimDuration | 20000000 | JPY |
| Gain on sales of noncurrent assets ei | InterimDuration | 4450000000 | JPY |
| Gain on sales of investment securities ei | Prior1InterimDuration | 143000000 | JPY |
| Gain on sales of investment securities ei | InterimDuration | － | JPY |
| State subsidy ei | Prior1InterimDuration | 2000000 | JPY |
| State subsidy ei | InterimDuration | 2253000000 | JPY |
| Other ei | Prior1InterimDuration | 14000000 | JPY |
| Other ei | InterimDuration | 4000000 | JPY |
| Extraordinary income | Prior1InterimDuration | 179000000 | JPY |
| Extraordinary income | InterimDuration | 6708000000 | JPY |
| Loss on retirement of noncurrent assets el | Prior1InterimDuration | 124000000 | JPY |
| Loss on retirement of noncurrent assets el | InterimDuration | 95000000 | JPY |
| Loss on reduction of noncurrent assets el | Prior1InterimDuration | － | JPY |
| Loss on reduction of noncurrent assets el | InterimDuration | 2050000000 | JPY |
| Loss on product recall el | Prior1InterimDuration | 201000000 | JPY |
| Loss on product recall el | InterimDuration | － | JPY |
| Other el | Prior1InterimDuration | 296000000 | JPY |
| Other el | InterimDuration | 349000000 | JPY |
| Extraordinary loss | Prior1InterimDuration | 621000000 | JPY |
| Extraordinary loss | InterimDuration | 2494000000 | JPY |
| Income before income taxes | Prior1InterimDuration | 4051000000 | JPY |
| Income before income taxes | InterimDuration | 12448000000 | JPY |
| Income taxes current | Prior1InterimDuration | 2913000000 | JPY |
| Income taxes current | InterimDuration | 6098000000 | JPY |
| Income taxes deferred | Prior1InterimDuration | 324000000 | JPY |
| Income taxes deferred | InterimDuration | -283000000 | JPY |
| Income taxes | Prior1InterimDuration | 3237000000 | JPY |
| Income taxes | InterimDuration | 5814000000 | JPY |
| Profit loss | Prior1InterimDuration | 813000000 | JPY |
| Profit loss | InterimDuration | 6633000000 | JPY |
| Profit loss attributable to non controlling interests | Prior1InterimDuration | 684000000 | JPY |
| Profit loss attributable to non controlling interests | InterimDuration | 728000000 | JPY |
| Profit loss attributable to owners of parent | Prior1InterimDuration | 129000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |